Here is the design of a clinical trial:

Official Title: Personalized Recommendations for Acute Kidney Injury (AKI) Care Using a Kidney Action Team: A Randomized Trial

Included conditions:
- Acute Kidney Injury

Study Armgroups:
- {'label': 'Usual Care', 'type': 'NO_INTERVENTION', 'description': 'Kidney Action Team Recommendations will not be delivered to the primary care teams of randomized patients.'}
- {'label': 'Kidney Action Team Recommendations', 'type': 'EXPERIMENTAL', 'description': "Recommendations made by the Kidney Action Team will be delivered to the patient's primary care team within 30 minutes of AKI development.", 'interventionNames': ['Other: Kidney Action Team Recommendations']}

Interventions:
- {'type': 'OTHER', 'name': 'Kidney Action Team Recommendations', 'description': "Upon review of the patient's medical information, the Kidney Action Team will create personalized recommendations that will be delivered to the patient's primary care team via a specialized note in the electronic medical record system within 30 minutes of AKI development. The attending of record will be identified as a cosigner to ensure that a member of the care team is made aware of the note's presence.", 'armGroupLabels': ['Kidney Action Team Recommendations']}

Primary Outcomes:
- {'measure': 'Composite outcome showing the percentage of participants with any one of the following: progression of AKI, inpatient dialysis, or inpatient death', 'description': 'Progression of AKI is defined by an increase in KDIGO creatinine stage from that present at the time of randomization.\n\nDialysis is defined by the receipt of hemodialysis, continuous renal replacement therapy or peritoneal dialysis. Isolated ultrafiltration treatments (for the purpose of volume removal) will not be included.\n\nMortality will be determined from hospital administrative records.\n\nThe rates of the primary outcome will be compared between the study arms using the Cochrane-Mantel-Haenszel chi-square test, accounting for stratification by hospital.', 'timeFrame': '14 days post randomization or at hospital discharge'}

Please estimate the sample size based on the assumption: 
To achieve 90% power at an alpha of 0.05, with an additional 10% increase to account for contamination.
Power and sample size
        The overall sample size of the study is based on the composite outcome of AKI progression, dialysis and death. The baseline rate for this outcome is 21% based on preliminary data, and a 20% improvement rate would be considered clinically meaningful. To achieve 90% power, at an alpha of 0.05, we would need to enrol 1824 patients in each randomisation arm of the study for an overall total of 3624. However, given concerns about contamination, we have increased this overall number by almost 10% for a final total of 4000 patients. Enrolment of 4000 individuals allows us to maintain detection of a difference in the rate of adherence of 10% of 1 SD at an alpha of 0.05.